We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cell Genesys, Inc. and Takeda Pharmaceutical Company Limited, together with its wholly owned subsidiary Millennium: The Takeda Oncology Company, announced that they have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.

Under the terms of the agreement, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.